Altered Hepatobiliary Disposition of Tolvaptan and Selected Tolvaptan Metabolites in a Rodent Model of Polycystic Kidney Disease

James J. Beaudoin; Jacqueline Bezençon; Yanguang Cao; Katsuhiko Mizuno; Sharin E. Roth; William J. Brock; Kim L. R. Brouwer

doi:10.1124/dmd.118.083907

Research ArticleArticle

Altered Hepatobiliary Disposition of Tolvaptan and Selected Tolvaptan Metabolites in a Rodent Model of Polycystic Kidney Disease

James J. Beaudoin, Jacqueline Bezençon, Yanguang Cao, Katsuhiko Mizuno, Sharin E. Roth, William J. Brock and Kim L. R. Brouwer

Drug Metabolism and Disposition February 2019, 47 (2) 155-163; DOI: https://doi.org/10.1124/dmd.118.083907

James J. Beaudoin

Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, North Carolina (J.J.B., J.B., Y.C., K.L.R.B.); Tokushima Research Institute, Otsuka Pharmaceutical Co., Ltd., Tokushima, Japan (K.M.); Otsuka Pharmaceutical Development & Commercialization, Inc., Rockville, Maryland (S.E.R.); and Brock Scientific Consulting, LLC, Montgomery Village, Maryland (W.J.B.)

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site
ORCID record for James J. Beaudoin

Jacqueline Bezençon

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Yanguang Cao

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Katsuhiko Mizuno

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Sharin E. Roth

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

William J. Brock

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Kim L. R. Brouwer

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site
ORCID record for Kim L. R. Brouwer

Article
Figures & Data
Info & Metrics
eLetters
PDF + SI
PDF

Submit a Response to This Article

Compose eLetter

Title *

Contents

More information about text formats

Plain text

No HTML tags allowed.
Web page addresses and e-mail addresses turn into links automatically.
Lines and paragraphs break automatically.

Author Information

Contributors
First Name and Middle Initial * First or given name, e.g. 'Peter'. Last Name * Your last, or family, name, e.g. 'MacMoody'. Email Address * Your email address, e.g. higgs-boson@gmail.com Occupation * Your role and/or occupation, e.g. 'Orthopedic Surgeon'. Affiliation * Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.

Statement of Competing Interests

Competing interests? *

Yes

Please describe the competing interests

Vertical Tabs

Jump to comment:

No eLetters have been published for this article.

PreviousNext

In this issue

Drug Metabolism and Disposition

Vol. 47, Issue 2

1 Feb 2019

Table of Contents
Table of Contents (PDF)
About the Cover
Index by author
Editorial Board (PDF)
Front Matter (PDF)

Download PDF

Article Alerts

User Name *

Password *

Email *

Email Article

Thank you for sharing this Drug Metabolism & Disposition article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Your Email *

Your Name *

Send To *

Enter multiple addresses on separate lines or separate them with commas.

You are going to email the following Altered Hepatobiliary Disposition of Tolvaptan and Selected Tolvaptan Metabolites in a Rodent Model of Polycystic Kidney Disease

Message Subject (Your Name) has forwarded a page to you from Drug Metabolism & Disposition

Message Body (Your Name) thought you would be interested in this article in Drug Metabolism & Disposition.

Your Personal Message

Citation Tools

Research ArticleArticle